Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 5/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778277 | 1.00 | F10 (0.49) | F10ACKR3NPC1CCR3TAS1R3 | |
| SCHEMBL14368754 | 0.86 | NPC1 (0.48) | NPC1CCR3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14392662 | 0.85 | CCR3 (0.44) | CCR3 | |
| SCHEMBL27757451 | 0.84 | CCR3 (0.48) | ACKR3NPC1CCR3 | |
| SCHEMBL14368703 | 0.82 | CHRNA7 (0.51) | F10NPC1MCHR1MAPT | |
| SCHEMBL14392352 | 0.82 | CHRNA7 (0.51) | F10NPC1MCHR1MAPT | |
| SCHEMBL27757300 | 0.82 | CHRNA7 (0.51) | F10NPC1MCHR1MAPT | |
| SCHEMBL28944630 | 0.80 | TAS1R3 (0.49) | F10ACKR3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14368778 | 0.80 | TAS1R3 (0.49) | F10ACKR3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14368686 | 0.77 | HRH3 (0.57) | NPC1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | F10 232/4885ACKR3 278/4885NPC1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.